KIAA1429 / VIRMA promotes breast cancer progression by m 6 A ‐dependent cytosolic HAS2 stabilization

  • Li N
  • Zhu Z
  • Deng Y
  • et al.
26Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

N 6 ‐methyladenosine (m 6 A), the most abundant internal modification in eukaryotic mRNA, plays important roles in many physiological and pathological processes, including the development and progression of cancer. RNA modification by m 6 A is regulated by methyltransferases, demethylases, and m 6 A‐binding proteins that function in large part by regulating mRNA expression and function. Here, we investigate the expression of m 6 A regulatory proteins in breast cancer. We find that expression of KIAA1429/VIRMA, a component of the m 6 A methyltransferase complex, is upregulated in breast cancer tissue and correlates positively with poor survival. KIAA1429/VIRMA is mislocalized to the cytosol of breast cancer tissues and cell lines, and shRNA‐mediated knockdown inhibits breast cancer cell proliferation, migration, and invasion. Mechanistically, KIAA1429/VIRMA is shown to bind to the m 6 A‐dependent RNA‐binding protein insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), leading to recruitment and stabilization of m 6 A‐modified hyaluronan synthase 2 (HAS2) mRNA. HAS2 mRNA and KIAA1429/VIRMA mRNA levels correlate positively in breast cancer tissues, suggesting that the KIAA1429/VIRMA–IGF2BP3–HAS2 axis promotes breast cancer growth and contributes to poor prognosis. image The m 6 A methyltransferase complex component KIAA1429/VIRMA is upregulated and mislocalized to the cytosol in breast cancer tissues and cell lines. A KIAA1429/VIRMA–IGF2BP3–HAS2 axis promotes breast cancer growth and might contribute to poor prognosis. Expression and cytosolic distribution of KIAA1429/VIRMA are elevated in breast cancer tissue and cell lines. KIAA1429/VIRMA depletion reduces HAS2 mRNA m 6 A levels, RNA stability, and expression. Cytosolic KIAA1429/VIRMA interacts with m 6 A binder IGF2BP3 and enhances HAS2 mRNA expression. HAS2 plays an essential role for KIAA1429/VIRMA‐mediated breast cancer cell proliferation and migration.

Cite

CITATION STYLE

APA

Li, N., Zhu, Z., Deng, Y., Tang, R., Hui, H., Kang, Y., & Rana, T. M. (2023). KIAA1429 / VIRMA promotes breast cancer progression by  m 6 A  ‐dependent cytosolic HAS2 stabilization. EMBO Reports, 24(10). https://doi.org/10.15252/embr.202255506

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free